Vinci Pharmaceuticals closed an $8 million-plus Series A led by Dynagrow Capital to fund manufacturing, testing, and first-in-human studies of its EPIPLANT platform.
- Amount
- $8M
- Stage
- Series A
- Announced
- 8 October 2026
- Lead
- Dynagrow Capital, LLLP
- Other investors
- MintPharma Capital
- Use of funds
- GMP manufacturing, testing and release activities of the EPIPLANT VCI-002 product, and the Phase 1/2a study in 2027
- Total raised
- $16.5M to date
- Checked
- Announced by the company